Scott A. Estes
Scott A. Estes's purchase track record
Scott A. Estes has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/23/2022 | JBGS | $232K | -13.2% | -19.4% | -3.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Evercore ISI Keeps Underperform on JBG SMITH, Lowers Target to $12. Evercore ISI Group kept its Underperform rating on JBG SMITH Properties and reduced its price target to $12. The new target matches the average analyst target of $12 and sits below the current support level of $14.39. The stock’s RSI of 25.8 indicates oversold conditions, which may affect market perception.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Truist lowers EPRT price target to $31, maintains Buy rating. Truist Securities has taken over coverage of Essential Properties Realty Trust, setting a new price target of $31 while keeping a Buy rating. This move comes as rising interest rates continue to pressure the real estate investment trust sector, though the company’s 4.72% dividend yield is noted as a factor that may help it remain resilient compared to peers.
Transaction History
| AHR | ▲ Buy | Grant | 2,594 | $0 | 6/24/2026 | View on chart |
| JBGS | ▼ Sell | Open Market | 10,000 | $199K | 10/30/2025 | View on chart |
| AHR | ▲ Buy | Grant | 3,042 | $0 | 6/25/2025 | View on chart |
| EPRT | ▲ Buy | Grant | 3,818 | $0 | 5/14/2025 | View on chart |
| AHR | ▲ Buy | Grant | 3,610 | $0 | 11/7/2024 | View on chart |
| JBGS | ▼ Sell | Open Market | 20,000 | $345K | 11/1/2024 | View on chart |
| AHR | ▼ Sell | Other | 4,836 | — | 8/5/2024 | View on chart |
| AHR | ▼ Sell | Other | 4,836 | — | 8/5/2024 | View on chart |
| EPRT | ▲ Buy | Grant | 3,631 | $0 | 5/20/2024 | View on chart |
| AHR | ▲ Buy | Grant | 7,407 | $0 | 2/9/2024 | View on chart |
| EPRT | ▲ Buy | Grant | 3,988 | $0 | 6/15/2023 | View on chart |
| AHR | ▲ Buy | Grant | 3,025 | $0 | 6/15/2023 | View on chart |
| AHR | ▲ Buy | Grant | 7,244 | $0 | 8/30/2022 | View on chart |
| JBGS | ▲ Buy | Open Market | 10,000 | $232K | 8/23/2022 | View on chart |
| EPRT | ▲ Buy | Grant | 4,323 | $0 | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
AHR Sets Q3 2026 Earnings Date Amid Sector Lag
American Healthcare REIT has announced the dates for its third-quarter 2026 earnings release and conference call. Recent commentary notes that the stock has lagged other finance stocks this year, though some analysts view the current price level as an opportunity driven by senior-care trends. With the stock trading near its 52-week low, the upcoming earnings report will be a key event for investors watching the company's performance.
AHR Sets Q3 2026 Earnings Date Amid Sector Lag. American Healthcare REIT has announced the dates for its third-quarter 2026 earnings release and conference call. Recent commentary notes that the stock has lagged other finance stocks this year, though some analysts view the current price level as an opportunity driven by senior-care trends. With the stock trading near its 52-week low, the upcoming earnings report will be a key event for investors watching the company's performance.